CoChat

Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes

Open access
Samtani, Mahesh N., Raghavan, Nandini, Shi, Yingqi, Novak, Gerald, Farnum, Michael, Lobanov, Victor, Schultz, Tim, Yang, Eric, DiBernardo, Allitia, Narayan, Vaibhav A., the Alzheimer' s Disease Neuroimaging Initiative · 2013 · British Journal of Clinical Pharmacology
Cited by 52

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Amnestic mild cognitive impairment MCI) represents the prodromal stage of Alzheimer's dementia and this disease progresses in a non‐linear fashion. • Disease progression depends on a variety of demographic, biochemical, genetic and cognitive factors. WHAT THIS STUDY ADDS • Baseline CSF biomarkers carry information about disease pathology and critical thresholds for these markers (Aβ and p‐tau 181P) have been identified that allow segregation of the population into MCI progressers and non‐progressers. AIM The objective is to develop a semi‐mechanistic disease progression model for mild cognitive impairment (MCI) subjects. The model aims to describe the longitudinal progression of ADAS‐cog scores from the Alzheimer's disease neuroimaging initiative trial that had data from 198 MCI subjects with cerebrospinal fluid (CSF) information who were followed for 3 years. METHOD Various covariates were tested on disease progression parameters and these variables fell into six categories: imaging volumetrics, biochemical, genetic, demographic, cognitive tests and CSF biomarkers. RESULTS CSF biomarkers were associated with both baseline disease score and disease progression rate in subjects with MCI. Baseline disease score was also correlated with atrophy measured using hippocampal volume. Progression rate was also predicted by executive functioning as measured by the Trail B‐test. CONCLUSION CSF biomarkers have the ability to discriminate MCI subjects into sub‐populations that exhibit markedly different rates of disease progression on the ADAS‐cog scale. These biomarkers can therefore be utilized for designing clinical trials enriched with subjects that carry the underlying disease pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2012.04308.x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 52

Metadata

Authors
Samtani, M. N., Raghavan, N., Shi, Y., Novak, G., Farnum, M., Lobanov, V., Schultz, T., Yang, E., DiBernardo, A., Narayan, V. A., & Initiative, T. A. S. D. N.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2012-12-14
Volume
75
Issue
1
Pages
146-161
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1598503899
Cited by
52
References
10
FWCI
3.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. https://app.cochat.ai/papers/10.1111/j.1365-2125.2012.04308.x
The paper
Samtani, M. N., Raghavan, N., Shi, Y., Novak, G., Farnum, M., Lobanov, V., Schultz, T., Yang, E., DiBernardo, A., Narayan, V. A., & Initiative, T. A. S. D. N. (2013). Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2012.04308.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.